US 9,808,427 B2
Swallowable N-acetylcysteine tablets
Alessandra De Lazzari, Padua (IT); and Alberto Moretto, Ponte San Niccolo′ (IT)
Assigned to ZAMBON S.P.A., Bresso (Milan) (IT)
Appl. No. 14/893,100
Filed by ZAMBON S.P.A., Bresso, MI (US)
PCT Filed May 27, 2014, PCT No. PCT/EP2014/060950
§ 371(c)(1), (2) Date Nov. 23, 2015,
PCT Pub. No. WO2014/191410, PCT Pub. Date Dec. 4, 2014.
Claims priority of application No. MI2013A0874 (IT), filed on May 29, 2013.
Prior Publication US 2016/0113876 A1, Apr. 28, 2016
Int. Cl. A61K 9/20 (2006.01); A61K 31/198 (2006.01); A61K 9/16 (2006.01)
CPC A61K 9/2054 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2027 (2013.01); A61K 9/2095 (2013.01); A61K 31/198 (2013.01); A61K 9/1688 (2013.01)] 11 Claims
 
1. A swallowable tablet consisting of at least 80% by weight of N-acetylcysteine, at least one binder in a quantity of 5% or more, at least one disintegrating agent in a quantity of 5% or more, at least one diluent in a quantity of 5% or more, at least one lubricant in quantity of 1% or less, and at least one glidant in a quantity of 1% or less, wherein all percentages are expressed by weight with respect to the total weight of the tablet, wherein said tablet is manufactured using a granulate prepared by a process of the dry granulation of N-acetylcysteine alone.